AVAX Technologies, Inc. (AVXT)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2007 | 7.37 Million USD | 142.34% |
| 2006 | 3.04 Million USD | -58.57% |
| 2005 | 7.34 Million USD | 101.76% |
| 2004 | 3.64 Million USD | 0.6% |
| 2003 | 3.62 Million USD | -52.08% |
| 2002 | 7.55 Million USD | -51.11% |
| 2001 | 15.45 Million USD | -49.66% |
| 2000 | 30.69 Million USD | 104.66% |
| 1999 | 15 Million USD | 35.14% |
| 1998 | 11.1 Million USD | -36.21% |
| 1997 | 17.4 Million USD | -21.97% |
| 1996 | 22.3 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2008 Q1 | 4.99 Million USD | -32.33% |
| 2008 Q2 | 2.78 Million USD | -44.26% |
| 2008 Q3 | 1.36 Million USD | -50.87% |
| 2007 Q3 | 8.98 Million USD | -11.95% |
| 2007 Q1 | 2.3 Million USD | -24.43% |
| 2007 Q2 | 10.2 Million USD | 343.48% |
| 2007 FY | 7.37 Million USD | 142.34% |
| 2007 Q4 | 7.37 Million USD | -17.88% |
| 2006 Q2 | 5.13 Million USD | -18.27% |
| 2006 Q3 | 3.9 Million USD | -23.98% |
| 2006 FY | 3.04 Million USD | -58.57% |
| 2006 Q4 | 3.04 Million USD | -22.0% |
| 2006 Q1 | 6.28 Million USD | -14.53% |
| 2005 Q4 | 7.34 Million USD | -15.76% |
| 2005 Q1 | 4.76 Million USD | 30.75% |
| 2005 Q2 | 9.94 Million USD | 108.83% |
| 2005 FY | 7.34 Million USD | 101.76% |
| 2005 Q3 | 8.72 Million USD | -12.28% |
| 2004 FY | 3.64 Million USD | 0.6% |
| 2004 Q4 | 3.64 Million USD | -15.77% |
| 2004 Q1 | 3.1 Million USD | -14.21% |
| 2004 Q2 | 5.23 Million USD | 68.61% |
| 2004 Q3 | 4.32 Million USD | -17.44% |
| 2003 Q4 | 3.62 Million USD | 3.0% |
| 2003 Q1 | 5.08 Million USD | -32.69% |
| 2003 FY | 3.62 Million USD | -52.08% |
| 2003 Q3 | 3.51 Million USD | -15.66% |
| 2003 Q2 | 4.16 Million USD | -18.06% |
| 2002 Q3 | 9.12 Million USD | -20.1% |
| 2002 Q1 | 13.79 Million USD | -10.75% |
| 2002 FY | 7.55 Million USD | -51.11% |
| 2002 Q4 | 7.55 Million USD | -17.22% |
| 2002 Q2 | 11.42 Million USD | -17.17% |
| 2001 FY | 15.45 Million USD | -49.66% |
| 2001 Q4 | 15.45 Million USD | -27.53% |
| 2001 Q1 | 26.51 Million USD | -13.62% |
| 2001 Q3 | 21.32 Million USD | -10.83% |
| 2001 Q2 | 23.91 Million USD | -9.83% |
| 2000 Q4 | 30.69 Million USD | -25.77% |
| 2000 Q2 | 36.55 Million USD | -6.25% |
| 2000 Q3 | 41.35 Million USD | 13.15% |
| 2000 FY | 30.69 Million USD | 104.66% |
| 2000 Q1 | 38.98 Million USD | 159.92% |
| 1999 Q3 | 14.8 Million USD | -11.38% |
| 1999 Q2 | 16.7 Million USD | -11.64% |
| 1999 Q1 | 18.9 Million USD | 70.27% |
| 1999 FY | 15 Million USD | 35.14% |
| 1999 Q4 | 15 Million USD | 1.35% |
| 1998 Q1 | 14.8 Million USD | -14.94% |
| 1998 Q2 | 13.3 Million USD | -10.14% |
| 1998 Q3 | 12 Million USD | -9.77% |
| 1998 Q4 | 11.1 Million USD | -7.5% |
| 1998 FY | 11.1 Million USD | -36.21% |
| 1997 Q1 | 20.3 Million USD | 0.0% |
| 1997 FY | 17.4 Million USD | -21.97% |
| 1997 Q4 | 17.4 Million USD | -6.45% |
| 1997 Q2 | 19.2 Million USD | -5.42% |
| 1997 Q3 | 18.6 Million USD | -3.13% |
| 1996 FY | 22.3 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -319257.446% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -276.734% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 30.101% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1236.151% |
| Rebus Holdings, Inc. | 5000.00 USD | -147443.14% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 94.334% |
| Qrons Inc. | 420.00 USD | -1756365.952% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -857.272% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 73.6% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1435.126% |
| Skye Bioscience, Inc. | 11.94 Million USD | 38.217% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 81.01% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -2.18% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -9561.782% |
| SQZ Biotechnologies Company | 107.18 Million USD | 93.117% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -415.153% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -10094.372% |
| Mesoblast Limited | 667.9 Million USD | 98.895% |
| Marizyme, Inc. | 22.01 Million USD | 66.49% |
| Genus plc | 1.02 Billion USD | 99.283% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -443.096% |
| Pharming Group N.V. | 462.85 Million USD | 98.406% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -122.672% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1378.273% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1076.58% |
| ContraFect Corporation | 20.67 Million USD | 64.325% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -1789.805% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -1830.299% |
| IMV Inc. | 31.33 Million USD | 76.456% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -77.933% |
| MultiCell Technologies, Inc. | 126.22 USD | -5844581.508% |
| ONE Bio Corp. | 70.08 Million USD | 89.474% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -685.064% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 94.259% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1608.807% |
| Q BioMed Inc. | 3.51 Million USD | -109.846% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 79.03% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -2723.5% |
| Biomind Labs Inc. | 73.81 Thousand USD | -9893.575% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 98.347% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -409.176% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 75.422% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -168.618% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -973.063% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -183.388% |
| GB Sciences, Inc. | 103.44 Thousand USD | -7031.684% |
| Alpha Cognition Inc. | 2.45 Million USD | -200.842% |
| HST Global, Inc. | 1526.00 USD | -483330.996% |
| CSL Limited | 38.02 Billion USD | 99.981% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -646.701% |
| Halberd Corporation | 10.13 Thousand USD | -72717.659% |
| Enzolytics Inc. | 361.7 Million USD | 97.96% |
| Agentix Corp. | 261.39 Thousand USD | -2722.258% |
| Resverlogix Corp. | 8.11 Million USD | 9.092% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -292.845% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.838% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 84.535% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1053.301% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -32282.938% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 17.566% |
| Zenith Capital Corp. | 7410.00 USD | -99456.775% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.782% |
| Ember Therapeutics, Inc. | 184.00 USD | -4009224.457% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2192.424% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -2722.56% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -694.986% |
| Kadimastem Ltd | 2.3 Million USD | -220.178% |
| Helix BioMedix, Inc. | 3.02 Million USD | -143.866% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 86.002% |
| BioStem Technologies, Inc. | 14.56 Million USD | 49.334% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -12821.072% |
| LadRx Corporation | 2.3 Million USD | -219.651% |
| Cell Source, Inc. | 195.17 Thousand USD | -3679.843% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1986.2% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1986.2% |
| NovAccess Global Inc. | 62.24 Thousand USD | -11751.235% |
| Affymax, Inc. | 7.44 Million USD | 0.885% |
| Itoco Inc. | 1.4 Million USD | -426.913% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -7612.093% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -6859.582% |
| Mobile Lads Corp. | 52.00 USD | -14186740.385% |
| CytoDyn Inc. | 11.13 Million USD | 33.754% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -5059.861% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -41159.267% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -1813.803% |
| SYBLEU INC | 330.46 Thousand USD | -2132.336% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1701.847% |
| International Stem Cell Corporation | 5.39 Million USD | -36.867% |
| Bioxytran, Inc. | 137.63 Thousand USD | -5259.826% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 50.825% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 55.503% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -9238.173% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -753.169% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 1.86% |
| Neutra Corp. | 2851.00 USD | -258656.822% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 77.235% |
| PureTech Health plc | 693.97 Million USD | 98.937% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 8.598% |
| IXICO plc | 15.84 Million USD | 53.439% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 10.925% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 92.86% |
| CSL Limited | 38.02 Billion USD | 99.981% |
| Cellectis S.A. | 333.99 Million USD | 97.791% |